Microbiome venture can start production in Denmark and Switzerland
The Danish Medicines agency has inspected Bacthera, a joint venture between Danish enzyme giant Chr. Hansen and Swiss Lonza, and has authorized the company to start producing bacteria for medical purposes in Denmark. The Swiss health authorities have also given the go-ahead.
BY ALBERT RØNNING ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Bioscience company Chr. Hansen and Swiss biotech firm Lonza have obtained permission to launch the production of bacteria for pharmaceutical use in their production facilities in Denmark and Switzerland.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Investors demand tax transparency from GN Store Nord
For subscribers
Food allergy venture to boost ALK's growth
For subscribers
